Recommended Dose of Ursodeoxycholic Acid in Adults with Cirrhosis
For adults with cirrhosis due to primary biliary cholangitis (PBC), ursodeoxycholic acid should be dosed at 13-15 mg/kg/day, divided into 2-3 doses daily. 1, 2
Dosing Algorithm
Standard Dosing for PBC-Related Cirrhosis
- Dose: 13-15 mg/kg/day divided into 2-3 daily doses
- This is first-line therapy and should be initiated at diagnosis 2
- Continue indefinitely, even if alkaline phosphatase remains elevated, as survival benefits persist 1, 2
Key Implementation Points
Do NOT exceed 15 mg/kg/day:
- Increasing beyond this dose does not improve biochemical response or symptoms 1, 2
- Higher doses have not demonstrated additional benefit in clinical trials 3
Timing of response assessment:
- Monitor liver enzymes every 3 months during the first year 2
- Assess biochemical response at 6-12 months after initiation 2
- For high-risk patients (liver stiffness ≥10 kPa, age <62 years), assess response as early as 6 months 2
Evidence Supporting This Dose
The 13-15 mg/kg/day dosing is supported by the most recent 2026 AGA/AASLD guidelines with strong recommendation and moderate certainty of evidence 1, 2. This dose has been shown to:
- Improve liver biochemistries (reduces bilirubin by ~8.69 μmol/L and alkaline phosphatase by ~257 U/L) 1
- Delay histologic progression (absolute risk reduction of 145 fewer patients with progression per 1000 treated) 1
- Improve transplant-free survival when initiated at early disease stages 4
Critical Caveats
This dosing applies specifically to PBC-related cirrhosis. The evidence provided does not support UDCA use for cirrhosis from other etiologies (e.g., viral hepatitis, alcohol-related, NASH). The FDA label 5 lists different dosing for gallstone dissolution (8-10 mg/kg/day) and prevention (600 mg/day), which are not applicable to cirrhosis management.
Do not discontinue UDCA if alkaline phosphatase remains elevated - the drug still provides sustained survival benefits even without complete biochemical normalization 1, 2. In such cases, consider adding second-line therapy (PPAR agonists like elafibranor 80 mg/day or seladelpar 10 mg/day) rather than stopping UDCA 2.
Inadequate response is defined as: failure to achieve alkaline phosphatase <1.5-1.67 times upper limit of normal AND normal total bilirubin at 12 months 2. This triggers consideration for add-on therapy, not dose escalation.
Practical Dosing Example
For a 70 kg adult with PBC-related cirrhosis:
- Target dose: 910-1050 mg/day (13-15 mg/kg × 70 kg)
- Practical dosing: 900-1050 mg/day divided into 2-3 doses
- This aligns with research showing 900 mg/day (approximately 13.5 mg/kg/day for average-weight patients) as optimal 3